mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases

E-ISSN： 1873-4286|17|35|3888-3897

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.35, 2011-12, pp. : 3888-3897

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases

Current Pharmaceutical Design, Vol. 9, Iss. 3, 2003-01 ,pp. : 201-220

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR inhibitors as a new therapeutic option for epilepsy

By Curatolo Paolo Moavero Romina

Expert Review of Neurotherapeutics, Vol. 13, Iss. 6, 2013-06 ,pp. : 627-638

Informa Healthcare

Access to resources Recommend Favorite

The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

Current Pharmaceutical Design, Vol. 20, Iss. 1, 2014-01 ,pp. : 125-135

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems

Current Drug Targets, Vol. 16, Iss. 10, 2015-09 ,pp. : 1107-1132

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 5, Iss. 3, 2005-09 ,pp. : 315-322

Bentham Science Publishers

Access to resources Recommend Favorite